Project Grant W81XWH2110827

This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development (CFDA 12.420) program, provides $1,754,922.00 to the HHT Foundation International, Inc. (doing business as Cure HHT) for a 2-year project period from July 1, 2025 to June 30, 2027. The purpose of this award is to conduct an extension trial to evaluate the drug pazopanib for treating Hereditary Hemorrhagic Telangiectasia (HHT)-related bleeding. HHT is a rare...

This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $742,984 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a 3-center, double-blind, placebo-controlled, randomized Phase II clinical trial testing whether the drug empagliflozin can improve heart function and other outcomes in patients with pulmonary arterial hypertension. The...

This federal Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $866,246 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a 24-week, randomized, triple-masked clinical trial to determine if the drug empagliflozin can improve right ventricular (RV) function in patients with pulmonary arterial hypertension (PAH). The primary endpoint is...

The University of Washington has been awarded a $1,947,532.70 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct a Phase 2 clinical trial evaluating the safety and efficacy of the angiotensin receptor blocker valsartan in adults with pulmonary arterial hypertension (PAH) and right heart failure. The 4-year study, which will run from September 2024 to June 2028, aims to determine if valsartan can improve six-minute walk...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA Program #93.350, provides funding of $489,500 to The Children's Hospital of Philadelphia (CHOP) Research Institute to conduct research on a potential treatment for Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM). The research aims to study the effects of a small compound called Repsox on correcting the platelet defects and reducing the risk of leukemic transformation in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $662,096 to the Beckman Research Institute of the City of Hope to conduct research on improving the response rates for patients with locally advanced rectal cancer (LARC) through the use of a mitochondrial inhibitor, papaverine, in combination with radiation therapy. The key objectives are to: 1) determine the safety of combining papaverine with short-course high-dose radiation therapy,...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $242,310 to Tulane University to evaluate the impact of loss of heterozygosity on localized arteriovenous malformation (AVM) formation in hereditary hemorrhagic telangiectasia (HHT). The research aims to develop an HHT mouse model of SMAD4 loss of heterozygosity, compare it to...

This federal Project Grant award, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, is funding a multi-center clinical trial to evaluate the effectiveness of progestin treatments for heavy menstrual bleeding among adolescents and young adults with heritable bleeding disorders. The $910,994 award, effective September 15, 2024, will support a 4-year study comparing outcomes related to bleeding management, quality of...

This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports a 5-year, $706,669 multi-site clinical trial to evaluate the effects of photobiomodulation therapy (PBMT) on chronic lymphedema in head and neck cancer survivors. The study aims to assess the impact of PBMT on the severity of external and internal lymphedema, symptom burden, functional impairments, and quality of life. The project will enroll 150...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $438,682 to The Johns Hopkins University to conduct a multi-center observational study on silent cerebral infarction (SCI) in patients with immune thrombotic thrombocytopenic purpura (iTTP). The key objectives are to: 1) elucidate the natural history of SCI and establish the incidence and risk factors for new SCI and...